Doxazosin
"Doxazosin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A prazosin-related compound that is a selective alpha-1-adrenergic blocker.
Descriptor ID |
D017292
|
MeSH Number(s) |
D03.633.100.786.750.200
|
Concept/Terms |
Cardura- Cardura
- Cardular
- Zoxan
- Carduran
Doxazosin Mesylate- Doxazosin Mesylate
- Mesylate, Doxazosin
- 1 (4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-((2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl)piperazine
Doxazosin-ratiopharm- Doxazosin-ratiopharm
- Doxazosin ratiopharm
- ratio-Doxazosin
- ratio Doxazosin
- Doxazosina Ratiopharm
- Ratiopharm, Doxazosina
|
Below are MeSH descriptors whose meaning is more general than "Doxazosin".
Below are MeSH descriptors whose meaning is more specific than "Doxazosin".
This graph shows the total number of publications written about "Doxazosin" by people in this website by year, and whether "Doxazosin" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
2003 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Doxazosin" by people in Profiles.
-
Margolis KL, Piller LB, Ford CE, Henriquez MA, Cushman WC, Einhorn PT, Colon PJ, Vidt DG, Christian R, Wong ND, Wright JT, Goff DC. Blood pressure control in Hispanics in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension. 2007 Nov; 50(5):854-61.
-
Davis BR, Piller LB, Cutler JA, Furberg C, Dunn K, Franklin S, Goff D, Leenen F, Mohiuddin S, Papademetriou V, Proschan M, Ellsworth A, Golden J, Colon P, Crow R. Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Circulation. 2006 May 09; 113(18):2201-10.
-
Crawford ED, Wilson SS, McConnell JD, Slawin KM, Lieber MC, Smith JA, Meehan AG, Bautista OM, Noble WR, Kusek JW, Nyberg LM, Roehrborn CG. Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol. 2006 Apr; 175(4):1422-6; discussion 1426-7.
-
Barzilay JI, Davis BR, Bettencourt J, Margolis KL, Goff DC, Black H, Habib G, Ellsworth A, Force RW, Wiegmann T, Ciocon JO, Basile JN. Cardiovascular outcomes using doxazosin vs. chlorthalidone for the treatment of hypertension in older adults with and without glucose disorders: a report from the ALLHAT study. J Clin Hypertens (Greenwich). 2004 Mar; 6(3):116-25.
-
Barqawi A, Gamito E, O'Donnell C, Crawford ED. Herbal and vitamin supplement use in a prostate cancer screening population. Urology. 2004 Feb; 63(2):288-92.
-
McConnell JD, Roehrborn CG, Bautista OM, Andriole GL, Dixon CM, Kusek JW, Lepor H, McVary KT, Nyberg LM, Clarke HS, Crawford ED, Diokno A, Foley JP, Foster HE, Jacobs SC, Kaplan SA, Kreder KJ, Lieber MM, Lucia MS, Miller GJ, Menon M, Milam DF, Ramsdell JW, Schenkman NS, Slawin KM, Smith JA. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003 Dec 18; 349(25):2387-98.
-
Barzilay JI, Jones CL, Davis BR, Basile JN, Goff DC, Ciocon JO, Sweeney ME, Randall OS. Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Diabetes Care. 2001 Apr; 24(4):654-8.
|
People People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|